Despite Panel Thumbs-Up, Analysts Downplay Absorb Market Impact
This article was originally published in The Gray Sheet
While a panel of FDA experts almost unanimously voted to recommend Abbott's fully bioabsorbable Absorb scaffold, analysts say the stent is unlikely to take significant market share, at least in its current form.
You may also be interested in...
Abbott looks to Absorb GT1, the first fully bioresorbable coronary scaffold to gain FDA approval, to help accelerate growth. But it still has yet to be shown superior to conventional drug-eluting stents, and it also has metal stents with bioresorbable polymers to contend with.
James Blankenship, the outgoing president of the Society for Cardiovascular Angiography and Interventions, spoke to The Gray Sheet following the positive panel recommendation for Abbott's fully bioabsorbable Absorb stent.
An FDA panel meets March 15 to discuss Abbott's PMA for the firm's fully absorbable Absorb scaffold. Pre-meeting materials give a generally positive view of the device, but they highlight some elevated adverse-event rates.